Teva Outlines US Opportunities Amid North American Decline
Future Targets Include Generic Symbicort And Alvotech-Partnered Humira Biosimilar
With Teva continuing to report declining North American generics sales – albeit more than offset by increases in other territories and business units – the company has highlighted future targets in the US as it pushes forward with its new “pivot to growth” strategy.
